These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34181077)

  • 1. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    Chisari CG; Comi G; Filippi M; Paolicelli D; Iaffaldano P; Zaffaroni M; Brescia Morra V; Cocco E; Marfia GA; Grimaldi LM; Inglese M; Bonavita S; Lugaresi A; Salemi G; De Luca G; Cottone S; Conte A; Sola P; Aguglia U; Maniscalco GT; Gasperini C; Ferrò MT; Pesci I; Amato MP; Rovaris M; Solaro C; Lus G; Maimone D; Bergamaschi R; Granella F; Di Sapio A; Bertolotto A; Totaro R; Vianello M; Cavalla P; Bellantonio P; Lepore V; Patti F;
    J Neurol; 2022 Feb; 269(2):933-944. PubMed ID: 34181077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
    Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
    CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.
    Evdoshenko E; Stepanova A; Shumilina M; Davydovskaya M; Khachanova N; Neofidov N; Kalinin I; Popova E; Dubchenko E; Pozhidaeva N; Volkov A; Sivertseva S; Prilenskaya A; Malkova N; Korobko D; Vergunova I; Shchur S; Makshakov G
    PLoS One; 2019; 14(5):e0217303. PubMed ID: 31136608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
    Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
    Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
    Mathew T; Kamath V; John SK; Netravathi M; Iyer RB; Raghavendra S; Kumar S; Neeharika ML; Gupta S; Murgod U; Shivakumar R; Annadure RK; Ichaporia N; Rohatgi A; Nair SS; Yareeda S; Anand B; Singh P; Renukaradhya U; Arulselvan V; Reddy YM; Surya N; Sarma GRK; Nadig R; Deepalam S; Sharath Kumar GG; Satishchandra P; Singhal BS; Parry G
    Mult Scler Relat Disord; 2022 Oct; 66():104059. PubMed ID: 35908446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
    Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M;
    Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.
    Prosperini L; Annovazzi P; Capobianco M; Capra R; Buttari F; Gasperini C; Galgani S; Solaro C; Centonze D; Bertolotto A; Pozzilli C; Ghezzi A
    Mult Scler; 2015 Nov; 21(13):1713-22. PubMed ID: 25698174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    Monschein T; Dekany S; Zrzavy T; Ponleitner M; Altmann P; Bsteh G; Kornek B; Rommer P; Enzinger C; Di Pauli F; Kraus J; Berger T; Leutmezer F; Guger M;
    J Neurol; 2023 Aug; 270(8):3779-3786. PubMed ID: 37074388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
    Vukusic S; Rollot F; Casey R; Pique J; Marignier R; Mathey G; Edan G; Brassat D; Ruet A; De Sèze J; Maillart E; Zéphir H; Labauge P; Derache N; Lebrun-Frenay C; Moreau T; Wiertlewski S; Berger E; Moisset X; Rico-Lamy A; Stankoff B; Bensa C; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Vaillant M; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Tourbah A; Guennoc AM; Hankiewicz K; Patry I; Nifle C; Maubeuge N; Labeyrie C; Vermersch P; Laplaud DA;
    JAMA Neurol; 2020 Jan; 77(1):94-102. PubMed ID: 31479149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.